A caveat to interpreting causality of soluble ligands in patient sera to attenuated NKG2D receptor levels is the presence of transforming growth factor β (TGFβ) that also diminishes NKG2D, as reported in GBM (55). Here, KLRK1 is linked to glioblastoma.